# US 2010/0168152 A1 · Fat regulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168152 A1
- Document ID: US20100168152A1
- Status: Published application
- Kind: A1
- Application number: 12/589,229
- Filed: 2009-10-19
- Published: 2010-07-01
- Earliest claimed: 2002-12-06
- Assignees: FibroGen, Inc.
- Inventors: Patrick D. Fourney; Volkmar Guenzler-Pukall; Stephen J. Klaus; Al Y. Lin; Thomas B. Neff; Todd W. Seeley
- Web page: https://patentgrep.com/patent/US20100168152A1

## CPC

- A61K 31/70: Carbohydrates; Sugars; Derivatives thereof (sorbitol A61K31/047)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods and compounds for regulating fat metabolism and achieving fat homeostasis in a subject. Methods and compound for regulating body weight, reducing body fat, and inducing weight loss are also provided, as are methods and compounds for treating or preventing obesity and for preventing or treating conditions associated with altered fat metabolism including, e.g., obesity, diabetes, atherosclerosis, etc.

## Claims

### Claim at position 1

-33. (canceled)

### Claim 34

A method for treating obesity in an obese subject, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound which inhibits a hypoxia inducible factor (HIF) hydroxylase, thereby treating the obesity in the subject.

### Claim 35

A method for regulating body weight in a subject in need thereof, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound which inhibits a HIF hydroxylase, thereby regulating body weight in the subject.

### Claim 36

A method for reducing body fat in a subject in need thereof, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound which inhibits a HIF hydroxylase, thereby reducing body fat in the subject.

### Claim 37

A method for reducing serum triglyceride levels in a subject in need thereof, the method comprising administering to the subject an effective amount of a heterocyclic carboxamide compound which inhibits a HIF hydroxylase, thereby reducing triglyceride levels in the subject.

### Claim 38 (depends on 36)

The method of claim 36, wherein the body fat is visceral fat.

### Claim 39 (depends on 36)

The method of claim 36, wherein the body fat is abdominal fat.

### Claim 40 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the HIF hydroxylase is a HIF prolyl hydroxylase.

### Claim 41 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the subject is a mammal.

### Claim 42 (depends on 41)

The method of claim 41, wherein the mammal is a human.

### Claim 43 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the subject is a human with body mass index (BMI) between 25.0 and 29.9.

### Claim 44 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein subject is a human with a body mass index (BMI) at or above 30.

### Claim 45 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the subject is a male human with a percentage body fat of greater than 25%.

### Claim 46 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the subject is a female human with a percentage body fat of greater than 31%.

### Claim 47 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound is a quinoline carboxamide.

### Claim 48 (depends on 47)

The method of claim 47, wherein the quinoline carboxamide is a quinoline-2-carboxamide.

### Claim 49 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound is a quinoline carbonyl glycine.

### Claim 50 (depends on 49)

The method of claim 49, wherein the quinoline carbonyl glycine is a quinoline-2-carbonyl glycine.

### Claim 51 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound is an isoquinoline carboxamide.

### Claim 52 (depends on 51)

The method of claim 51, wherein the isoquinoline carboxamide is an isoquinoline-3-carboxamide.

### Claim 53 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound is an isoquinoline carbonyl glycine.

### Claim 54 (depends on 53)

The method of claim 53, wherein the isoquinoline carbonyl glycine is an isoquinoline-3-carbonyl glycine.

### Claim 55 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound a pyridine carboxamide, a pyrimidine carboxamide, a cinnoline carboxamide, or a beta-carboline carboxamide.

### Claim 56 (depends on 55)

The method of claim 55, wherein the pyridine carboxamide is a 3-hydroxypyridine carboxamide

### Claim 57 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide compound is selected from the group consisting of a pyridine carbonyl glycine, and a pyrimidine carbonyl glycine.

### Claim 58 (depends on 57)

The method of claim 57, wherein the pyridine carbonyl glycine is a 3-hydroxypyridine carbonyl glycine or a 3-methoxy pyridine carbonyl glycine.

### Claim 59 (depends on 37)

The method of claim 37, wherein the compound is selected from the group consisting of [(7-Chloro-3-hydroxy-quinoline-2-carbonyl)-amino]-acetic acid, [(1-Chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid, [(4-Hydroxy-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, [(1-Chloro-4-hydroxy-7-methoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, [(3-Hydroxy-6-isopropoxy-quinoline-2-carbonyl)-amino]-acetic acid, [(3-Hydroxy-pyridine-2-carbonyl)-amino]-acetic acid, and [(7-Benzyloxy-1-chloro-4-hydroxy-isoquinoline-3-carbonyl)-amino]-acetic acid methyl ester.

### Claim 60 (depends on 34, 35, 36)

The method of any one of claim 34, 35, 36, or 37, wherein the heterocyclic carboxamide is a heterocyclic carbonyl glycine selected from the group consisting of a quinoline-2-carboxamide, an isoquinoline-3-carboxamide, a 3-methoxy pyridine carbonyl glycine, a 3-hydroxypyridine carbonyl glycine, and a 5-sulfonamidocarbonyl pyridine carboxylate.